Objectives: To use a pre-clinical infection model to assess the antibacterial effect of human simulations of dosing with ceftolozane/tazobactam (with or without amikacin) or meropenem against Enterobacteriaceae and Pseudomonas aeruginosa.
Introduction
Ceftolozane/tazobactam has been licensed for use in Europe and North America in the treatment of complicated urinary tract infection and complicated intra-abdominal infection (cIAI). It is undergoing Phase III trials for ventilator-associated bacterial pneumonia. 1 However, much clinical interest has focused on its use in the treatment of Pseudomonas aeruginosa infections, including MDR strains. Recent subgroup analysis of patients with cIAI who had P. aeruginosa isolated indicated that the response in ceftolozane/tazobactam-treated patients was similar to that in patients treated with meropenem. 2 Similarly, salvage therapy with ceftolozane/tazobactam for multi-resistant P. aeruginosa infection has been described. 3, 4 Most patients with MDR P. aeruginosa infection had shock or pneumonia and 25% died. 3 In all these studies the number of patients was small; furthermore, P. aeruginosa is a rare cause of community-acquired cIAI. 5 Ceftolozane/tazobactam is potent against many Enterobacteriaceae, including ESBL-producing strains, and P. aeruginosa, including MDR isolates. In studies of isolates from European hospitals the MIC 50 for Escherichia coli was 0.25 mg/L and the MIC 90 was 0.5 mg/L, whereas the MIC 50 for Klebsiella was 0.5 mg/L and the MIC 90 for Klebsiella pneumoniae was .32 mg/L. 6 For drug-resistant P. aeruginosa (mainly OprD mutants) the ceftolozane/tazobactam MIC 90 was 4 mg/L (range 0.25-64 mg/L). 7 The pharmacokinetics of ceftolozane and tazobactam have been described in healthy volunteers. 8, 9 A 2 g dose of ceftolozane produced a C max of 140 mg/L and a serum t1 =2 of 2.6 h, and a 1 g dose produced a C max of 90 mg/L with t1 =2 2.6 h; equivalent values for tazobactam at 0.5 g were C max 18 mg/L and t1 =2 1.0 h. Pre-clinical pharmacodynamic studies in mice and in vitro indicated ceftolozane is fT .MIC driven, with an fT .MIC for 24 h resulting in 0, 1 and 2 log drops in initial bacterial load for P. aeruginosa (25%-30%, 27%-40% and 30%-40%, respectively). [10] [11] [12] Preclinical pharmacokinetic models have also been used to model human courses of ceftolozane/tazobactam monotherapy and combination therapy against Staphylococcus aureus but as yet not against Gram-negative aerobic bacilli. 13 The aim of this study was to define the antibacterial effect of ceftolozane/tazobactam at simulated mean human serum concentrations over 7 days against E. coli, K. pneumoniae and P. aeruginosa. Meropenem was used as comparator for monotherapy simulations and a combination of ceftolozane/tazobactam plus amikacin was simulated against P. aeruginosa.
Materials and methods

In vitro pharmacokinetic model
An in vitro one-compartment pharmacokinetic model (Electrolab, Tewkesbury, UK) was used to simulate the free-drug serum concentrations associated with standard doses of ceftolozane/tazobactam, meropenem and amikacin. The apparatus, which has been described many times before, 14 consists of a central culture chamber for infusion of ceftolozane, meropenem or amikacin, ensuring the correct t1 =2 , connected via aluminium and silicone tubing to a reservoir containing broth. The central culture chamber is also connected to a waste vessel via silicone tubing. Owing to the differing serum t1 =2 values of ceftolozane and tazobactam (2.5 and 1 h, respectively) the model was supplemented with ceftolozane throughout each dosing period via a separate dosing chamber to achieve the required concentration-time profiles for both ceftolozane and tazobactam. 15 The temperature was maintained at 37 C and the broth constantly agitated, with an initial inoculum of 10 6 cfu/mL.
Antimicrobials
Ceftolozane and tazobactam were supplied by Merck and Co. Inc., Kenilworth, NJ, USA. Meropenem and amikacin were sourced from Sigma, Poole, UK, and solutions were prepared according to the manufacturers' instructions.
Medium
Unsupplemented Mueller-Hinton broth was used for all experiments.
Bacteria
Three strains of E. coli, two of K. pneumoniae and five of P. aeruginosa were used ( Table 1 ). All of the strains studied were clinical strains. Two of the E. coli and both K. pneumoniae were CTX-M-15 producers and three P. aeruginosa overexpressed AmpC enzymes. There was no genetic characterization performed on the K. pneumoniae strains. Three of the P. aeruginosa strains had higher ceftolozane/tazobactam MICs (!2 mg/L) than the others; one contained an OprD porin mutation and all three showed AmpC overexpression. These strains were used in the amikacin combination experiments.
Bacterial killing curves
Viable counts were determined using a spiral plater (Don Whitley, Shipley, UK). Aliquots were plated onto nutrient agar plates after neutralization with b-lactamase for determination of viable counts. Phosphocellulose P81 paper was used to neutralize amikacin. The minimum level of detection was 2%10 2 cfu/mL. Aliquots were taken hourly from time 0 to 8 h then every 8 h until 168 h (7 days) and stored at #70 C for determination of drug concentrations. All experiments were performed in triplicate.
Pharmacokinetics
Free-drug serum concentrations of ceftolozane/tazobactam at 1 g/0.5 g and 2 g/1 g q8h were modelled (i.e. a 1 g ceftolozane peak free concentration of 58 mg/L after a 1 h infusion, t1 =2 2.5 h; and tazobactam peak free concentration of 16 mg/L after 1 h of infusion, t1 =2 1 h). 8, 15 For 2 g ceftolozane/ 1 g tazobactam, the C max at 1 h of infusion was 112 mg/L for ceftolozane and 32 mg/L for tazobactam, and the t1 =2 values were as with other dose simulations. Free-drug concentrations were modelled assuming a free fraction of 0.8 for both agents. 16 Meropenem concentrations modelled were those associated with 2 g q8h as a bolus (i.e. C max 100 mg/L and t1 =2 1 h Noel et al.
assuming a free fraction of 0.98). Amikacin was simulated at two doses in combination with ceftolozane/tazobactam at 2 g/1 g (amikacin at 15 mg/kg q24h, C max 50 mg/L, t1 =2 2.5 h; and amikacin at 7.5 mg/kg q12h, C max 25 mg/L, t1 =2 2.5 h, assuming a free fraction of 0.9).
Antibiotic assays
Ceftolozane, tazobactam and meropenem concentrations were measured using HPLC methodology. The stationary phase for ceftolozane and tazobactam was Gemini-NX SuC18 (100%4.6 mm) (Phenomenex, Macclesfield, UK). The mobile phase composition was 98% phosphate buffer, 1% acetonitrile and 1% orthophosphoric acid. The wavelength was 254 nm for ceftolozane and 220 nm for tazobactam; detection was by UV absorbance using a Dionex UltiMate 3000 variable wavelength detector (Thermo Fisher, Hemel Hempstead, UK) and a flow rate of 1.8 mL/min. Aqueous samples of 10 lL were injected and retention was $5-6 min for ceftolozane and 3-4 min for tazobactam. The lower limit of detection was 1.0 mg/L for both compounds. The stationary phase for meropenem was Hypersil 5 ODS (100%4.6 mm; Phenomenex, Macclesfield, UK). The mobile phase composition was 25% methanol, 1% phosphoric acid and 74% water and wavelength was 330 nm; detection was by UV absorbance using a Dionex Ultimate 3000 variable wavelength detector (Thermo Fisher, Hemel Hempstead, UK) and a flow rate of 1.0 mL/min. Aqueous samples of 10 lL were injected and retention was $5-6 min. The lower limit of detection was 1.0 mg/L. Amikacin concentrations were measured by competitive inhibition immunoassay using the Indiko Plus V R QMS System (Thermo Fisher, Hemel Hempstead, UK); the lower limit of detection was ,1.5 mg/L.
Measurement of antibacterial effects and emergence of resistance
Antibacterial effect was measured by log change in viable count over the duration of simulations (log cfu/mL). The antibacterial endpoints were log change in viable count from initial inoculum (time 0) at 24, 48, 72, 96, 120, 144 and 168 h as well as the area under the bacterial kill curve (AUBKC; log cfu/mLÁh) between time 0 and 24, 48, 72, 96, 120, 144 and 168 h. AUBKC at 168 h (AUBKC 168 ) was the co-primary endpoint along with emergence of resistance measured by growth on 4 % MIC plates. Emergence of resistance was assessed using population profiles 14 at time zero (pre-exposure) and every 24 h subsequently up to 168 h. Samples were plated onto agar containing no antibiotic and antibiotic at 2 % MIC and 4 % MIC to quantify resistant sub-populations; in population studies for ceftolozane, tazobactam was added at a fixed concentration of 4 mg/L. The limit of detection was 2%10 2 cfu/mL, strains from !4 % MIC plates recovered at 168 h were stored and MICs were measured using CLSI agar dilution methodology.
Statistical analysis
Analysis was performed using a paired t-test for two comparators and oneway ANOVA for two or more comparators (Graph Pad Prism Version 4.0, Graph Pad Software, CA, USA).
Results
MICs and strains
The MICs of ceftolozane alone, ceftolozane/tazobactam and meropenem for the individual E. coli, K. pneumoniae and P. aeruginosa strains are shown in Table 1 . E. coli strains were susceptible (S) to ceftolozane/tazobactam by EUCAST categorization (S 1 mg/L), whereas the K. pneumoniae strains were ceftolozane/tazobactam resistant. In addition, two of the five strains of P. aeruginosa had MICs on the EUCAST clinical breakpoint (S 4 mg/L) for Pseudomonas spp. The P. aeruginosa strains 47237, 55759 and 55762 were used in combination with amikacin and all had amikacin MICs of 4 mg/L. Figure 1 shows the serum time profiles of the drugs measured.
Pharmacokinetic curves
Comparison of monotherapy simulations with q8h dosing of ceftolozane/tazobactam at 1 g/0.5 g or 2 g/1 g and meropenem at 2 g Bacterial clearance
Comparisons in the log change in viable count at 24, 96 and 168 h between the two ceftolozane/tazobactam and meropenem dosing regimens against E. coli (n " 3), K. pneumoniae (n " 2) and P. aeruginosa (n " 5) are shown in Table 2 and Figures S1, S2 and S3 (available as Supplementary data at JAC Online); AUBKC 24 , AUBKC 96 and AUBKC 168 are also shown for each regimen in Table 2 .
Against E. coli all three regimens produced a .4 log reduction in viable count by 24 h, which was sustained over the 168 h of simulated dosing. Employing AUBKC as the antibacterial effect measure, the meropenem AUBKCs were statistically smaller than those of the two ceftolozane/tazobactam regimens at 24, 96 and 168 h (P , 0.01). The two ceftolozane/tazobactam regimens had the same AUBKC values at 24 and 168 h (P " 0.6301 and P " 0.7314, respectively).
Ceftolozane/tazobactam had a different pattern of antibacterial activity against K. pneumoniae from E. coli (Table 2 and Figures S1 and S2) . Despite both strains of Klebsiella being resistant to ceftolozane/tazobactam, there was a 2-4 log drop in viable count up to 4-6 h of incubation but significant regrowth subsequently. Regrowth occurred subsequently with both regimens. The regimen of 2 g of meropenem was rapidly bactericidal, producing a .4 log reduction in viable count by 24 h that was sustained throughout the dosing simulation. Using AUBKC as the antibacterial effect measure for K. pneumoniae strains, a statistically significant difference was observed between the two ceftolozane/ tazobactam regimens and meropenem at 24, 96 and 168 h (P , 0.05, all three timepoints) reflecting the amount of regrowth seen with both strains. The two ceftolozane/tazobactam regimens had similar AUBKC 24 but the higher-dose regimen (2 g/1 g) produced a smaller AUBKC 168 than the low-dose regimen (Table 2) ; hence, it was more bactericidal.
Against the five P. aeruginosa strains employed in both ceftolozane/tazobactam regimens, a .4 log drop in initial viable count was observed by 4-6 h. There was subsequently some regrowth with four of the five strains over the 168 h of the simulation (Table 2 and Figure S3 ). Meropenem showed a similar pattern of antibacterial action over the whole simulation (Table 2) . Using AUBKC as the antibacterial effect measure there was no difference between the anti-pseudomonal effects of the three regimens at Ceftolozane/tazobactam ! amikacin: in vitro PK model of infection JAC 24 or 168 h; similarly, there was no difference between the two ceftolozane/tazobactam regimens or either of the ceftolozane/ tazobactam regimens and meropenem (P . 0.05).
Emergence of resistance
No change in population profiles was noted with E. coli: all three strains were eradicated from the model by all three dosing Noel et al.
simulations up to 168 h (Table S1 ) and no resistance was seen with any regimen. In contrast with K. pneumoniae by 168 h, six of six experiments with the low-dose regimen of ceftolozane/tazobactam produced colonies able to grow on 4 % MIC plates (count 7.6+0.5 log 10 cfu/mL). The high-dose ceftolozane/tazobactam regimen (Table S1 ) produced colonies on 4 % MIC plates in three of six experiments (count 7.5+0.1 log 10 cfu/mL). Subsequent MIC testing of these isolates showed an increase in the ceftolozane/ tazobactam MIC from 4 mg/L to .128 mg/L. There was no emergence of resistance with E. coli or K. pneumoniae to meropenem (Table S1 ). When P. aeruginosa strains were exposed to ceftolozane/tazobactam no isolates were recovered from 4 % MIC plates over the 168 h simulations. In contrast, for meropenem dosed 2 g q8h, by 168 h 7/15 experiments showed growth on 4 % MIC plates with a count of 4.4+1.5 log 10 cfu/mL (Table S1 ). MIC testing of these isolates did not generally show increased MICs, though occasional colonies had MICs of 8 mg/L.
Comparison of combination therapy simulations of q8h dosing of ceftolozane/tazobactam 1 g/0.5 g or 2 g/1 g with amikacin 15 mg/kg q24h or 7.5 mg/kg q12h simulations Bacterial clearance
Comparison of changes in viable count between ceftolozane/tazobactam (2 g/1 g) and ceftolozane/tazobactam (2 g/1 g) plus amikacin 15 mg/kg q24h or amikacin 7.5 mg/kg q12h are shown in Table 3 . The three strains of P. aeruginosa selected (strains 47237, 55759 and 55762) all had higher ceftolozane/tazobactam MICs, in the range 2-4 mg/L. The addition of amikacin 15 mg/kg q24h increased the initial rate of pseudomonal killing (Table 3 and Figure S4 ). This was reflected in the comparison of AUBKC at 24 and 168 h, which showed lower AUBKCs and hence greater bacterial killing (P , 0.05 at 24 and 168 h). Comparison of the regimens of amikacin once versus twice a day showed no significant differences in AUBKC at 24 or 168 h (P . 0.05, both comparisons).
There were no changes in population profiles with ceftolozane/ tazobactam plus amikacin with either the q24h or q12h amikacin simulations. With the simulations of amikacin twice a day there was growth on amikacin 4 % MIC plates in two of six experiments at 168 h (4.7 log 10 cfu/mL) but not with the q24h amikacin simulations. Amikacin MICs were not increased.
Discussion
In vitro pharmacokinetic models are increasingly being used to inform drug development 16 but also to guide therapeutic use of drugs after regulatory approval. Pre-clinical models can be used to simulate the full course of antimicrobial therapy up to 14 days or longer (for example see Louie et al.
17
) as well as to study antibiotic combinations in situations that are never likely to be studied in clinical trials (see Synder et al.
18
). Models provide information on changes in bacterial load but also the risk of emergence of resistance, 20 indicating the inverse U-shaped relationship between drug exposure and resistance as initially shown by MacGowan et al.
19
The present data indicate that standard doses of ceftolozane/ tazobactam (1 g/0.5 g q8h or 2 g/1 g q8h) are both highly effective at reducing E. coli bacterial load for strains with or without the CTX-M-15 enzyme and do not result in changes in population profiles or rises in MIC. Although meropenem is more bactericidal against E. coli when analysis is by AUBKC, ceftolozane/tazobactam also produces .4 log drops in count over 5 days.
These data are in keeping with our previous data and those of VanScoy et al., 21 which showed in in vitro models a marked bactericidal effect of ceftolozane/tazobactam against E. coli and ESBL Table 2 . Antibacterial effect of simulated human doses of ceftolozane/tazobactam or meropenem as monotherapy against E. coli (n " 3), K. pneumoniae (n " 2) and P. aeruginosa (n " 5) Ceftolozane/tazobactam ! amikacin: in vitro PK model of infection JAC producers, and suggested fT .MIC at 24 h of .44%+11% was associated with a .3 log kill. 21 Ceftolozane/tazobactam was markedly less bactericidal against K. pneumoniae at both 1 g/0.5 g and 2 g/1 g doses. This is in keeping with previous observations with another cephalosporin, ceftaroline, which showed that the fT .MIC change in bacterial load relationship with Klebsiella spp. was different from that with E. coli; specifically the fT .MIC to produce a !3 log reduction at 96 h was 55%+19% for E. coli but .100% for three of four strains of Klebsiella tested. 22 In addition, the CTX-M-containing K. pneumoniae had markedly higher MICs of ceftolozane/tazobactam than the E. coli strains and represent more challenging strains, so it is perhaps unsurprising that ceftolozane/tazobactam was less effective at reducing bacterial load and ceftolozane/tazobactam MICs were raised. Both the K. pneumoniae would have been classified as ceftolozane/tazobactam-resistant using EUCAST or FDA breakpoints; however, the addition of an aminoglycoside or other active second agent may overcome this resistance and would be worthy of further study.
P. aeruginosa is recognized to be a highly challenging target for antimicrobial chemotherapy: in in vitro models bactericidal endpoints and suppression of resistance require high drug exposures, often higher than human dosing as monotherapy. 23, 24 Combination therapy with a b-lactam, almost always a carbapenem, most often with the addition of tobramycin, has the effect of adding to the antibacterial kill while suppressing the risk of emergence of resistance using both in vitro and in vivo models. [25] [26] [27] [28] Interestingly, the addition of the b-lactamase inhibitor avibactam to cefepime also suppressed the emergence of resistance to cefepime in P. aeruginosa strains with AmpC production. 27 Ceftolozane/tazobactam was equally effective as meropenem against the five P. aeruginosa strains tested here; this included three strains with AmpC overexpression, one of which had an OprD mutation. The higher-dose simulation was modestly more effective at reducing pseudomonal bacterial load but this difference was not statistically significant. Unlike meropenem in our experiments and meropenem simulations by others, there was no emergence of resistance with ceftolozane/tazobactam, in contrast to meropenem; 26 this is perhaps related to the presence of the b-lactamase inhibitor tazobactam, 27 but not all our strains were enzyme producers. Addition of amikacin to ceftolozane/tazobactam, as expected, increased bacterial clearance from the model, amikacin being equally effective once or twice a day. Again, there was no emergence of resistance to ceftolozane/tazobactam; however, changes in amikacin population profiles were clear with the twicea-day amikacin regimen. These data suggest that addition of amikacin to ceftolozane/tazobactam in the treatment of P. aeruginosa will add to bacterial clearance but at the risk of amikacin resistance; this can be mitigated by use of once-a-day aminoglycoside treatment.
In conclusion, this work results in a hypothesis that ceftolozane/tazobactam will be effective therapy for E. coli (ceftolozane/ tazobactam MIC 0.25 mg/L) and P. aeruginosa (ceftolozane/ tazobactam MIC 4 mg/L) infection. Addition of amikacin once a day for P. aeruginosa has an additive effect for bacterial clearance without the risk of emergence of resistance.
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